Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-term survivors, yet the relevant antigens remain unknown. Here we use genetic, immunohistochemical and transcriptional immunoprofiling, computational biophysics, and functional assays to identify T-cell antigens in long-term survivors of pancreatic cancer. Using whole-exome sequencing and in silico neoantigen prediction, we found that tumours with both the highest neoantigen number and the most abundant CD8+ T-cell infiltrates, but neither alone, stratified patients with the longest survival. Investigating the specific neoantigen qualities promoting T-cell activation in long-term survivors, we discovered that these individuals were enriched in neoantigen qualities defined by a fitness model, and neoantigens in the tumour antigen MUC16 (also known as CA125). A neoantigen quality fitness model conferring greater immunogenicity to neoantigens with differential presentation and homology to infectious disease-derived peptides identified long-term survivors in two independent datasets, whereas a neoantigen quantity model ascribing greater immunogenicity to increasing neoantigen number alone did not. We detected intratumoural and lasting circulating T-cell reactivity to both high-quality and MUC16 neoantigens in long-term survivors of pancreatic cancer, including clones with specificity to both high-quality neoantigens and predicted cross-reactive microbial epitopes, consistent with neoantigen molecular mimicry. Notably, we observed selective loss of high-quality and MUC16 neoantigenic clones on metastatic progression, suggesting neoantigen immunoediting. Our results identify neoantigens with unique qualities as T-cell targets in pancreatic ductal adenocarcinoma. More broadly, we identify neoantigen quality as a biomarker for immunogenic tumours that may guide the application of immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In rare patients with localized PDAC who are long-term survivors, bacteria can translocate from the intestine into the tumour and control anti-tumour immune activation11,12.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [12]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, the gut microbiota can indirectly increase the immunogenicity of tumor cells by providing tumor cross-antigens to promote the efficacy of ICI [50, 68, 69].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PDAC tumors from long term survivors have high quantity and quality of neoantigens, and stronger infiltration and activation of CD8+ T cells”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data suggest that microbial host factors, independent of the genomic composition of the tumor, may determine tumor behavior and patient outcomes.”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Significantly, the aggressive progression of PDAC, characterized by immune evasion and therapeutic resistance, is heavily influenced by the TME (Balachandran et al., 2017).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829
Cited by
Items 801–900 of 1,001
Mauriello, A., Cavalluzzo, B., Manolio, C., Ragone, C., Luciano, A., Barbieri, A., Tornesello, M. L., Buonaguro, L., Tagliamonte, M., & Buonaguro, L. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03194-6 · Cited by 7
Ge, X., Liu, Z., Weng, S., Xu, H., Zhang, Y., Liu, L., Dang, Q., Guo, C., Beatson, R., Deng, J., et al. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.06.064 · Cited by 7
Halle-Smith, J. M., Pearce, H., Nicol, S. M., Hall, L. A., Powell-Brett, S. F., Beggs, A. D., Iqbal, T. H., Moss, P. A. H., & Roberts, K. J. (2024) · Cancers · doi:10.3390/cancers16050996 · Cited by 9
Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival
Richard, G., Groot, A. S. D., Steinberg, G. D., Garcia, T. I., Kacew, A. J., Ardito, M. T., Martin, W. D., Berdugo, G., Princiotta, M. F., Balar, A. V., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89016-7 · Cited by 6
Wang, Q. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189712 · Cited by 7
Bai, R.-L., Wang, N.-Y., Zhao, L., Zhang, Y., & Cui, J. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.08.012 · Cited by 6
Multi-Level Analysis and Identification of Tumor Mutational Burden Genes across Cancer Types
Wang, S., Tong, Y., Zong, H., Xu, X., Crabbe, M. J. C., Wang, Y., & Zhang, X. (2022) · Genes · doi:10.3390/genes13020365 · Cited by 6
De- “bug”-ing the microbiome in lung cancer
Birla, P., & Shaikh, F. Y. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10036-4 · Cited by 7
Computational Quantification of Cancer Immunoediting
Liu, K., He, S., Sun, S., Zhang, X., He, Y., Quan, F., Pang, B., & Xiao, Y. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0926 · Cited by 7
MUC16Mutations and Prognosis in Gastric Cancer
Smyth, E. C., & Fitzgerald, R. C. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2803 · Cited by 6
Computational methods in tumor immunology
Bhinder, B., & Elemento, O. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2020.01.001 · Cited by 7
Raufi, A. G., Pellicciotta, I., Palermo, C. F., Sastra, S. A., Chen, A., Alouani, E. L., Maurer, H. C., May, M. S., Iuga, A. C., Rabadán, R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.24.573257 · Cited by 7
Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and the CD155/TIGIT Pathway
la Torre, J. D., Joshi, U., Sonowal, H., Kuang, Y., Ren, T., Chen, D.-H., Tharuka, M. D. N., Nguyen-Ta, K., Gros, H. L., Mikulski, Z., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0129 · Cited by 8
Zhai, Z., Li, X., Shang, S., Ma, S., Liang, X., Yin, S., Wu, M., Yu, J., Song, Q., & Chen, D. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-025-02623-z · Cited by 5
Banday, A. H., Manzoor, M. M., Nissar, U., & Jaleel, S. (2026) · Scandinavian Journal of Immunology · doi:10.1111/sji.70084 · Cited by 7
Cancer Neoantigen Vaccines Emerge Efficacious
Sultan, H., & Schreiber, R. D. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-071723-045853 · Cited by 5
Lan, Y., Qing, J., Feng, M. H., Zhao, P., & Zhu, M. S. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1100020 · Cited by 5
C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients
Bonazzi, V., Aoude, L. G., Brosda, S., Bradford, J. J., Lonie, J. M., Loffler, K. A., Gartside, M. G., Patel, K., Mukhopadhyay, P., Keane, C., et al. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13993 · Cited by 8
Updates in Molecular Profiling of Pancreatic Ductal Adenocarcinoma
Lee, J. J., & Yeh, J. J. (2024) · Surgical Clinics of North America · doi:10.1016/j.suc.2024.04.001 · Cited by 7
Dietary auxin may help patients to fight cancer
López‐Bucio, J. (2024) · Trends in Plant Science · doi:10.1016/j.tplants.2024.10.016 · Cited by 5
Kluz, N., Kraj, L., Chmiel, P., Przybyłkowski, A. M., Wyrwicz, L. S., Stec, R., & Szymański, Ł. (2024) · Cancers · doi:10.3390/cancers16233945 · Cited by 5
Peptide-MHC I regulatory mechanisms and intervention strategies in anti-tumor T cell immunity
Zhang, Z., Shen, Y. J., Lin, Y.-S., Yang, B., Cao, J., Li, J., & Zhao, W. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01574-y · Cited by 7
Yousefli, Z., Rafiee, N., Nourollahian, T., Alipour, A., Haghshenas, Z., Islampanah, M., Khazaei, M., Fiuji, H., Hassanian, S. M., Ferns, G. A., et al. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156045 · Cited by 5
Biesel, E. A., Sundheimer, J., Badr, M. T., Posadas‐Cantera, S., Chikhladze, S., Fichtner‐Feigl, S., & Wittel, U. A. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1521952 · Cited by 6
Hu, L., Xiao, Y., Jiang, N., Hu, Y., Qiu, L., & Geng, B. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1569947 · Cited by 8
Wang, Y., Jin, B., Zhou, N., Sun, Z., Li, J., Chen, Q., Wu, X., Zhou, Y., Shi, Y. X., Lu, X., et al. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620999200918121456 · Cited by 5
Neoantigen Quantity and Quality in Relation to Pancreatic Cancer Survival
Levink, I. J. M., Brosens, L. A. A., Rensen, S. S., Aberle, M. R., Damink, S. W. M. O., Cahen, D. L., Buschow, S. I., Fuhler, G. M., Peppelenbosch, M. P., & Bruno, M. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.751110 · Cited by 5
Ballabio, F., Broggini, L., Paissoni, C., Han, X., Peqini, K., Sala, B. M., Sun, R., Sandalova, T., Barbiroli, A., Achour, A., et al. (2022) · ACS Omega · doi:10.1021/acsomega.1c06964 · Cited by 7
Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy
Baleeiro, R. B., Chard, L. S., Liu, P., Lu, S., Lone, Y. C., Lemoine, N. R., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.902709 · Cited by 6
Zhao, X., He, Y., Pan, Y., Ye, L., Liu, L., Mou, X., & Fu, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1044526 · Cited by 5
Current Clinical Landscape of Immunotherapeutic Approaches in Pancreatic Cancer Treatment
Farhangnia, P., Ghomi, S. M., Mollazadehghomi, S., & Delbandi, A. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_163 · Cited by 5
Exogenous or in situ vaccination to trigger clinical responses in pancreatic cancer
Beatty, G. L., & Jaffee, E. M. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae065 · Cited by 5
Wang, C., Shi, M., Zhang, L., Ji, J. F., Xie, R., Wu, C., Guo, X., Yang, Y., Zhou, W., Peng, C., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03012-4 · Cited by 6
Self-citationCancer metabolism challenges genomic instability and clonal evolution as therapeutic targets
Takeda, Y., Chijimatsu, R., Ofusa, K., Kobayashi, S., Doki, Y., Eguchi, H., & Ishii, H. (2022) · Cancer Science · doi:10.1111/cas.15279 · Cited by 5
An overview of cancer and the human microbiome
Mahapatra, S., Mohanty, S., Mishra, R., & Prasad, P. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.07.007 · Cited by 7
Untouchable genes in the human genome: Identifying ideal targets for cancer treatment
Gorlov, I. P., Gorlova, O. Y., & Amos, C. I. (2019) · Cancer Genetics · doi:10.1016/j.cancergen.2019.01.005 · Cited by 6
de Almeida, L. N., Audebert, C., Leschiera, E., & Lorenzi, T. (2022) · Mathematical Medicine and Biology A Journal of the IMA · doi:10.1093/imammb/dqac017 · Cited by 8
Innate and Adaptive Immune Responses to Cancer
Rausch, M. P., & Hastings, K. T. (2019) · Springer eBooks · doi:10.1007/978-3-030-15935-1_5 · Cited by 5
Perioperative immunotherapy for pancreatic cancer is on its way
Springfeld, C., Bailey, P. J., Hackert, T., & Neoptolemos, J. P. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-238 · Cited by 5
Brează, G. M., Cloşca, R. M., Cîndrea, A. C., Huţ, E. F., Cretu, O. M., Sima, L., Rakitovan, M., & Zara, F. (2025) · Diagnostics · doi:10.3390/diagnostics15050646 · Cited by 4
van Eijck, C. W. F., Ju, J., Land, F. R. V. ‘., Verheij, M., Li, Y., Stubbs, A., Doukas, M., Lila, K. A., Heij, L. R., Wiltberger, G. J., et al. (2024) · Pancreatology · doi:10.1016/j.pan.2024.08.014 · Cited by 5
Guo, G., Zhang, Z., Zhang, J., Wang, D., Xu, S., Wu, S., Deng, K., Bu, Y., Sheng, Z., Yu, J., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70733 · Cited by 4
Self-citationCancer Vaccination and Immune-Based Approaches in Pancreatic Cancer
Bloom, M. D., Shaikh, A. R., Sun, Z., Bashir, B., & Snook, A. E. (2025) · Cancers · doi:10.3390/cancers17142356 · Cited by 7
Lin, H., Zhou, J., Li, Y., Luo, L., Zeng, Y., Liang, X., Yu, J., Ye, C., Yang, P., Lin, Y., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117199 · Cited by 5
Novel Insights into T-Cell Exhaustion and Cancer Biomarkers in PDAC Using ScRNA-Seq
Saleem, M. U., Sajid, H. A., Arshad, M., Torres, A. R., Rai, S. K., & Arshad, M. W. (2025) · Biology · doi:10.3390/biology14081015 · Cited by 6
Fan, J., Chen, J., Wang, R., Peng, Y., Tan, S., Zhang, X., Tang, H., Chen, M., Li, B., & Yang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1599252 · Cited by 5
Sun, H., Gao, M., Liu, Z., Zg, Z., Li, X., Huang, H., Li, T., Shi, J., Yan, J., Sun, M., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01293-5 · Cited by 5
Crispim, J. G., Silva, C. N. P., Rêgo, M. J. B. D. M., & da Rosa, M. M. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178829 · Cited by 5
Christen, S. P., & Levine, A. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-20992-6_19 · Cited by 4
Self-citationWin or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer
Luo, W., Wang, Y., & Zhang, T. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02583-1 · Cited by 4
Immune pressure sculps tumor cells and trims high-quality mutations
Bassani‐Sternberg, M., & Harari, A. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.007 · Cited by 4
Biomarkers for immune checkpoint inhibitors in solid tumors
Kapoor, V., & Kelly, W. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02942-4 · Cited by 4
Vaccine boosts T cells that target pancreatic tumours
Huff, A. L., & Zaidi, N. (2023) · Nature · doi:10.1038/d41586-023-01526-8 · Cited by 4
Homan, E. J., & Bremel, R. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155679 · Cited by 4
Pathak, G. P., Shah, R., Castonguay, M., Cheng, A., Fris, J., Murphy, R. E., Darling, G. E., Ednie, A. C., French, D. G., Henteleff, H., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70262 · Cited by 6
Simunic, M., McGraw, K. L., Pavletic, S. Z., & Rashidi, A. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.10.006 · Cited by 4
Cancer neoantigens and immunogenicity: mutation position matters
Capietto, A.-H., Jhunjhunwala, S., & Delamarre, L. (2020) · Molecular & Cellular Oncology · doi:10.1080/23723556.2020.1740071 · Cited by 5
Neoadjuvante und adjuvante Therapie beim Pankreaskarzinom
Springfeld, C., Hackert, T., Jäger, D., Büchler, M. W., & Neoptolemos, J. P. (2020) · Der Chirurg · doi:10.1007/s00104-020-01169-9 · Cited by 4
Popper, H. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.40 · Cited by 5
Servín-Rojas, M., Fong, Z. V., Castillo, C. F.-D., Lionetto, G., Bolm, L., Fagenholz, P. J., Ferrone, C. R., Castellanos, D. M. R., Lillemoe, K. D., & Qadan, M. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006432 · Cited by 7
Next-generation algorithms for neoantigen selection
Hopkins, A. C., & Jaffee, E. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.184 · Cited by 4
Magrone, T., & Jirillo, E. (2019) · Current Pharmaceutical Design · doi:10.2174/138161282445190416154917 · Cited by 5
Symphony in chaos: Immune orchestra during pancreatic cancer progression
Sharma, P., Jain, T., Sethi, V., & Dudeja, V. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102787 · Cited by 4
Smorodin, E. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111608 · Cited by 4
Liu, T., Chen, J., Liu, A., Chen, L., Liang, X., Peng, J., Zheng, M.-H., Li, J., Cao, Y., & Shao, C. (2023) · Pancreas · doi:10.1097/mpa.0000000000002229 · Cited by 4
Maru, S. Y., Wetzel, M., Mitchell, J. T., Groß, N., Andaloori, L., Howe, K., Kartalia, E., Mo, G., Leatherman, J. M., Ho, W. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.27.645833 · Cited by 5
ERAP1 Allotypes 2 and 10 Differentially Regulate the Immunopeptidome of Melanocytes
Nikopaschou, M., Samiotaki, M. K., Kannavou, A., Angelis, N., Tsitsilonis, O., Panayotou, G., & Stratikos, E. (2025) · Immunology · doi:10.1111/imm.70056 · Cited by 3
NeoGuider: neoepitope prediction using advanced feature engineering
Zhao, X., Wei, L., Xie, Z., & Zhang, X. (2025) · Genome Medicine · doi:10.1186/s13073-025-01592-9 · Cited by 4
mRNA Vaccines for Cancer Treatment
Torphy, R. J., Balachandran, V., & Soares, K. C. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.10.006 · Cited by 3
Self-citationTargeting the gut-pancreatic axis: microbial modulation of immunotherapy in pancreatic cancer
Yuan, Y., Zhang, W., & Wang, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1682390 · Cited by 4
Fifteen challenges for generative AI applications to cell biology
Dupire, L., Khan, A. A., Karaletsos, T., Kelley, S., Lundberg, E. K., Ma, J., Paull, E., Quake, S. R., Rabadán, R., Cassius, R., et al. (2026) · Cell · doi:10.1016/j.cell.2026.07.004 · Cited by 4
Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches
Baretti, M., & Azad, N. S. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000390 · Cited by 4
Schwarz, S., Su, Z., Krohn, M., Loeffler, M. W., Schlösser, A., & Linnebacher, M. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00645-3 · Cited by 4
The Interplay Between DNA Repair and the Immune Microenvironment in Pancreatic Cancer
Ciner, A., Hosein, P. J., Jiang, Y., & Rassool, F. V. (2025) · Biomedicines · doi:10.3390/biomedicines13051031 · Cited by 3
Kanu, E. N., Fletcher, A. A., Bao, J., Agritelley, E. S., Button, J., Eckhoff, A. M., Comatas, K., Wang, T., Hwang, B.-J., Lidsky, M. E., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04146-5 · Cited by 3
Self-citationBrummel, K., Requesens, M., van Rooij, N., Workel, H. H., Eggink, F. A., Plat, A., Wardenaar, R., Spierings, D. C. J., Foijer, F., Church, D. N., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0083 · Cited by 3
Link, J. M., Liudahl, S. M., Betts, C. B., Sivagnanam, S., Leis, K. R., McDonnell, M., Pelz, C., Johnson, B., Hamman, K. J., Keith, D., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00287 · Cited by 4
Shanavas, M., Law, S. C., Hertzberg, M., Hicks, R. J., Seymour, J. F., Li, Z., de Long, L. M., Nath, K., Sabdia, M. B., Gunawardana, J., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1351 · Cited by 5
Lang, F., Sorn, P., Schrörs, B., Weber, D., Krämer, S., Şahin, U., & Löwer, M. (2023) · iScience · doi:10.1016/j.isci.2023.108014 · Cited by 3
Computational Methods for Predicting Key Interactions in T Cell–Mediated Adaptive Immunity
Ehrlich, R., Glynn, E., Singh, M., & Ghersi, D. (2024) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-102423-122741 · Cited by 3
Recent advancements in the cancer vaccines: A review
Kawish, S. M., Hilles, A. R., Sharma, S., Alam, M., Alimujiang, K., Iqbal, Z., Beg, S., Mahmood, S., & Mirza, M. A. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106422 · Cited by 3
Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management
Akce, M., & El‐Rayes, B. F. (2019) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2019.15.1.27 · Cited by 3
Karamitopoulou, E., & Gloor, B. (2019) · Cancers · doi:10.3390/cancers11070968 · Cited by 3
Das duktale Adenokarzinom des Pankreas: Subtypen und Molekularpathologie
Schlitter, A. M., Konukiewitz, B., Kasajima, A., Reichert, M., & Klöppel, G. (2021) · Der Pathologe · doi:10.1007/s00292-021-00965-2 · Cited by 3
Everybody In! No Bouncers at Tumor Gates
Vitale, I., & Galluzzi, L. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.12.006 · Cited by 3
Emerging clinical pharmacology topics in drug development and precision medicine
Liu, Q., Gilbert, J. A., Zhu, H., Huang, S. M., Kunkoski, E., Das, P., Bergman, K. L., Buschmann, M. M., & ElZarrad, M. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819869-8.00028-8 · Cited by 3
Zhan, Q., Zhang, L., Wen, C., Yang, Y., Jin, Y., Ren, D., Zhang, Z., Zou, S., Li, F., Sun, H., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000264 · Cited by 3
Self-citationImmunotherapy for Pancreatic Cancer
Sunami, Y., Rieder, S., Michl, P., & Kleeff, J. H. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_223-1 · Cited by 3
Does biology determine survival in pancreatic cancer?
Barreto, S. G. (2019) · Future Oncology · doi:10.2217/fon-2019-0706 · Cited by 3
Jin, Y., Huang, X., Wang, Z., Kouken, B., Wang, Q., & Wang, L. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101382 · Cited by 3
Molecular Mechanisms of Immune Resistance in Pancreatic Cancer: An Update
Pang, W. M., Lim, W., Ngai, Z. N., & Koh, R. Y. (2025) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010365485250330110031 · Cited by 2
Sun, Y., Wan, H., Xiong, J., Cao, K., Yang, D., & Huang, J. X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1559909 · Cited by 3
Ye, L., Dick, I. M., Robinson, B. W. S., Creaney, J., & Redwood, A. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04131-y · Cited by 3
Shafer, A. M., Kenna, E., Golden, L.-A. F., Elhossiny, A. M., Perry, K. D., Wilkowski, J. M., Yan, W., Kaczkofsky, B., McGue, J. J., Bresler, S. C., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1628 · Cited by 4
Redirecting cytomegalovirus immunity against pancreas cancer for immunotherapy
Marrocco, R., Patel, J., Medari, R., Salu, P., Lucero-Meza, E., Maia, C., Brunel, S., Martsinkovskiy, A., Sun, S., Gulay, K. C. M., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012969 · Cited by 2
Park, J. O., & Ryu, H. (2026) · Immune Network · doi:10.4110/in.2026.26.e12 · Cited by 3
Role of Gut Microbiota in Immune Checkpoint Inhibitor Therapy
Fu, Y.-C., Pang, B., & Liang, S. (2026) · Cell Biology International · doi:10.1002/cbin.70148 · Cited by 2
Yamashita, K., Fujita, M., Saito, M., Mukohyama, J., Miyashita, K., Ikeda, T., Kostrzewa, Y., Aoki, T., Harada, H., Otowa, Y., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-02997-1 · Cited by 4
Jin, X., Guan, X., Mu, Y., Wang, M., & Wang, C. (2026) · Discover Oncology · doi:10.1007/s12672-026-04808-5 · Cited by 3
Wang, X., Su, S., Tan, S., Chen, X., Wang, L., Wang, S., & Chen, F. (2026) · The Innovation · doi:10.1016/j.xinn.2026.101357 · Cited by 6
Metadata
- Authors
- Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., Senbabaoglu, Y., Wells, D. K., Cary, C. I. O., Grbovic-Huezo, O., Attiyeh, M., Medina, B., Zhang, J., Loo, J., Saglimbeni, J., Abu-Akeel, M., Zappasodi, R., Riaz, N., Smoragiewicz, M., Kelley, Z. L., Basturk, O., Gönen, M., Levine, A. J., Allen, P. J., Fearon, D. T., Merad, M., Gnjatic, S., Iacobuzio-Donahue, C. A., Wolchok, J. D., DeMatteo, R. P., Chan, T. A., Greenbaum, B. D., Merghoub, T., & Leach, S. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Swim Across America (US)
- University of Cambridge (GB)
- Cold Spring Harbor Laboratory (US)
- Corresponding author
- Balachandran, Vinod P.
- ORCID
- Balachandran, Vinod P.
- Łuksza, Marta
- Zhao, Julia N.
- Makarov, Vladimir
- Herbst, Brian
- Bhanot, Umesh
- Wells, Daniel K.
- Grbovic-Huezo, Olivera
- Attiyeh, Marc
- Medina, Benjamin
- Zappasodi, Roberta
- Riaz, Nadeem
- Smoragiewicz, Martin
- Gönen, Mithat
- Levine, Arnold J.
- Fearon, Douglas T.
- Gnjatic, Sacha
- Wolchok, Jedd D.
- DeMatteo, Ronald P.
- Chan, Timothy A.
- Greenbaum, Benjamin D.
- Merghoub, Taha
- Leach, Steven D.
- Venue
- Nature
- Published
- 2017-11
- Volume
- 551
- Issue
- 7681
- Pages
- 512-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6145146
- OpenAlex
- W2767699537
- Cited by
- 1,191
- References
- 28
- Citations by year
- 2026: 89 · 2025: 114 · 2024: 119 · 2023: 178 · 2022: 169 · 2021: 153 · 2020: 135 · 2019: 132 · 2018: 94 · 2017: 6
- FWCI
- 44.60
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (23526, 17263, 15678)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Agence Nationale de la Recherche (ANR-18-CE14-0005)
- National Institutes of Health
- National Cancer Institute (P01CA087497, P30-CA-08748, R01CA190400, P30CA008748, T32CA009501, K12CA184746)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097087)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pancreatic ductal adenocarcinoma, long-term survival, neoantigens, CA125, CD8+ T cells, T cell immunity, immunogenicity, mutational burden, immune evasion
- MeSH terms
- Cancer Survivors, Exome Sequencing, Adenocarcinoma, Antigens, Neoplasm, Bacterial Proteins, Computer Simulation, Cross Reactions, Humans, Immunotherapy, Membrane Proteins, Pancreatic Neoplasms, Prognosis, T-Lymphocytes, Cytotoxic, Survival Analysis, CA-125 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.